title: The specificity of JAK3 kinase inhibitors.
abstract: PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compound being evaluated in clinical trials for rheumatoid arthritis and prevention of allograft rejection. PF-956980 has been evaluated against a panel of 30 kinases, and found to have nanomolar potency against only JAK3. Cellular and whole blood activity of this compound parallels its potency and selectivity in enzyme assays. It was effective in vivo at inhibiting the delayed type hypersensivity reaction in mice. We compared 2 commercially available JAK3 inhibitors (WHI-P131 and WHI-P154) in the same panel of biochemical and cellular assays and found them to be neither potent nor selective for JAK3. Both were found to be nanomolar inhibitors of the EGF receptor family of kinases. As these compounds have been used in numerous publications in the transplant and autoimmune disease literature, their specificity should be considered when interpreting these results.
authors: Pfizer Global Research and Development, Groton, CT, USA. changelianps@gmail.com
authors: Paul S
authors: PS
authors: Changelian
authors: Deborah
authors: D
authors: Moshinsky
authors: Cyrille F
authors: CF
authors: Kuhn
authors: Mark E
authors: ME
authors: Flanagan
authors: Michael J
authors: MJ
authors: Munchhof
authors: Thomas M
authors: TM
authors: Harris
authors: David A
authors: DA
authors: Whipple
authors: Jonathan L
authors: JL
authors: Doty
authors: Jianmin
authors: J
authors: Sun
authors: Craig R
authors: CR
authors: Kent
authors: Kelly S
authors: KS
authors: Magnuson
authors: David G
authors: DG
authors: Perregaux
authors: Perry S
authors: PS
authors: Sawyer
authors: Elizabeth M
authors: EM
authors: Kudlacz
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D053616:Janus Kinase 3 / Q000037:antagonists & inhibitors*; D007700:Kinetics; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D004791:Enzyme Inhibitors; C554945:PF 956980; D011743:Pyrimidines; D011758:Pyrroles; D011799:Quinazolines; C116180:WHI P131; C113888:WHI P154; D011505:Protein-Tyrosine Kinases; D053616:Janus Kinase 3